X4 Pharmaceuticals Inc.

0.26
-0.01 (-4.09%)
At close: Mar 28, 2025, 3:59 PM
0.26
0.61%
Pre-market: Mar 31, 2025, 05:52 AM EDT

Company Description

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.

Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia.

The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies.

It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications.

The company was founded in 2010 and is headquartered in Boston, Massachusetts.

X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc. logo
Country United States
IPO Date Nov 16, 2017
Industry Biotechnology
Sector Healthcare
Employees 143
CEO Dr. Paula Ragan Ph.D.

Contact Details

Address:
61 North Beacon Street
Boston, Massachusetts
United States
Website https://www.x4pharma.com

Stock Details

Ticker Symbol XFOR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001501697
CUSIP Number 98420X103
ISIN Number US98420X1037
Employer ID 27-3181608
SIC Code 2836

Key Executives

Name Position
Dr. Paula Ragan Ph.D. Chief Executive Officer, President & Director
Adam S. Mostafa Chief Financial Officer, Treasurer & Corporate Secretary
Dr. Mary DiBiase Ph.D. Chief Operating Officer
Dr. Arthur Taveras Ph.D. Chief Scientific Officer
Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D. Chief Medical Officer
Dr. Keith T. Flaherty M.D. Founder & Member of Corporate Advisory Board
Dr. Renato T. Skerlj Ph.D. Founder
Dr. Richard Peters M.D., Ph.D. Chairman of the Board & Founder
Dr. Robert David Arbeit Senior Vice President of Clinical Development and Translational Research
Natasha Thoren Esq. Vice President, General Counsel & Compliance Officer

Latest SEC Filings

Date Type Title
Mar 26, 2025 S-8 Filing
Mar 26, 2025 10-K Annual Report
Mar 25, 2025 8-K Current Report
Mar 24, 2025 DEF 14A Filing
Mar 14, 2025 PRE 14A Filing
Mar 03, 2025 8-K Current Report
Feb 14, 2025 4 Filing
Feb 14, 2025 4 Filing
Feb 14, 2025 4 Filing
Feb 14, 2025 4 Filing